I'll analyze ASSET-01's eligibility for FDA expedited programs. Let me gather the facts and relevant criteria.
{
"id": "ASSET-01",
"name": "DLL3 CAR-T in relapsed/refractory ES-SCLC",
"indication": "Extensive-stage small cell lung cancer (ES-SCLC), 3rd line+",
"seriousness": "Serious / life-threatening (median OS in 3L+ SCLC is a few months).",
"modality": "Autologous CAR-T cell therapy (regenerative medicine).",
"unmet_need": "No approved targeted therapy in 3L+ SCLC; remaining options are low-response palliative chemo. Clear unmet need vs available therapy.",
"available_therapy": "Topotecan / lurbinectedin / re-challenge chemo (ORR ~15-20%, not durable).",
"clinical_evidence": "Phase 1/2: confirmed ORR 55% vs ~15-20% for available chemo, with early durability (several responders >6 months). Human data in hand.",
"endpoint_type": "Surrogate (objective response rate) \u2014 OS not yet mature.",
"prevalence_us": 35000,
"pediatric": false,
"phase": "Phase 1/2"
}{
"programs": [
{
"id": "fast_track",
"name": "Fast Track",
"type": "Development designation",
"benefit": "Rolling review, more frequent FDA meetings/written communication, and eligibility for Accelerated Approval and Priority Review if criteria later met."
},
{
"id": "breakthrough",
"name": "Breakthrough Therapy (BTD)",
"type": "Development designation",
"benefit": "All Fast Track features PLUS intensive FDA guidance on efficient drug development starting as early as Phase 1, and organizational commitment (senior managers / cross-disciplinary review)."
},
{
"id": "accelerated_approval",
"name": "Accelerated Approval (AA)",
"type": "Approval pathway",
"benefit": "Approval can occur YEARS earlier, on the surrogate/intermediate endpoint, before overall-survival-type outcomes mature."
},
{
"id": "priority_review",
"name": "Priority Review",
"type": "Review designation",
"benefit": "Shortens the FDA REVIEW CLOCK to ~6 months (vs ~10 months standard)."
},
{
"id": "rmat",
"name": "Regenerative Medicine Advanced Therapy (RMAT)",
"type": "Development designation (regenerative medicine)",
"benefit": "All Breakthrough features (early intensive guidance) PLUS explicit eligibility for Accelerated Approval on surrogate/intermediate endpoints and flexible confirmatory-evidence options (e.g. real-world data, expanded registries)."
},
{
"id": "orphan",
"name": "Orphan Drug Designation",
"type": "Incentive designation",
"benefit": "7 years of orphan market exclusivity on approval, tax credits for clinical trials, and waiver of the (large) PDUFA application user fee."
},
{
"id": "rare_pediatric",
"name": "Rare Pediatric Disease (RPD) Designation + Priority Review Voucher",
"type": "Incentive designation (pediatric)",
"benefit": "On approval of the RPD product, the sponsor receives a TRANSFERABLE Priority Review Voucher (PRV) \u2014 sellable for ~$100M+ \u2014 redeemable to get Priority Review on any future application."
}
],
"ema_analogues": {
"prime": "PRIME (PRIority MEdicines) \u2014 EMA's enhanced-support scheme, loosely analogous to Breakthrough Therapy; for medicines targeting an unmet need with early evidence of major therapeutic advantage. Often paired with conditional marketing authorisation.",
"conditional_ma": "Conditional Marketing Authorisation \u2014 EMA analogue of Accelerated Approval; approval on less complete data for a serious/unmet-need condition, with an obligation to provide confirmatory comprehensive data post-authorisation.",
"ema_orphan": "EU Orphan Designation \u2014 analogue of US Orphan Drug; prevalence threshold \u2264 5 in 10,000 in the EU, grants 10 years market exclusivity."
},
"note": "Designations are NOT mutually exclusive; a strong strategy stacks several. Use get_program_criteria for the full qualifying criteria of each program."
}{
"query": "small cell lung",
"count": 0,
"precedents": [
{
"drug": "Tisagenlecleucel (Kymriah)",
"indication": "Relapsed/refractory follicular lymphoma",
"modality": "Autologous CAR-T",
"designations": [
"RMAT",
"Accelerated Approval",
"Orphan Drug",
"Breakthrough Therapy (other indications)"
],
"note": "RMAT granted on preliminary Phase 2 ELARA data (ORR ~86%); later accelerated approval on response endpoints with a confirmatory obligation. Canonical CAR-T regenerative-medicine pathway precedent."
},
{
"drug": "Pembrolizumab (Keytruda)",
"indication": "Advanced melanoma (initial) and many oncology indications",
"modality": "Anti-PD-1 monoclonal antibody",
"designations": [
"Breakthrough Therapy",
"Accelerated Approval",
"Priority Review"
],
"note": "Initial melanoma approval was Accelerated Approval on durable ORR (a surrogate), with confirmatory trials required; a textbook surrogate-endpoint AA precedent for a naked mAb in oncology."
},
{
"drug": "Onasemnogene abeparvovec (Zolgensma)",
"indication": "Spinal muscular atrophy (rare fatal pediatric neuromuscular disease)",
"modality": "AAV gene therapy",
"designations": [
"RMAT",
"Breakthrough Therapy",
"Orphan Drug",
"Rare Pediatric Disease PRV",
"Priority Review"
],
"note": "Rare fatal pediatric gene therapy that stacked regenerative-medicine, orphan, and rare-pediatric-disease incentives \u2014 the model for a fatal pediatric gene-therapy designation stack."
},
{
"drug": "Zolbetuximab (Vyloy)",
"indication": "CLDN18.2+ gastric/GEJ adenocarcinoma",
"modality": "Naked monoclonal antibody",
"designations": [
"Orphan Drug (gastric)",
"Priority Review"
],
"note": "First-in-class naked mAb approved on a mature randomized endpoint \u2014 illustrates a non-regenerative asset using orphan + priority review rather than AA."
}
],
"note": "If no direct match, full precedent list returned for analogy."
}Now let me pull the detailed criteria for the most relevant programs to apply them precisely.
{
"id": "rmat",
"name": "Regenerative Medicine Advanced Therapy (RMAT)",
"type": "Development designation (regenerative medicine)",
"criteria": [
"Drug is a REGENERATIVE MEDICINE THERAPY (cell therapy, therapeutic tissue engineering, human cell/tissue product, or qualifying combination \u2014 e.g. CAR-T, gene therapy).",
"Intended to treat, modify, reverse, or cure a SERIOUS or life-threatening condition.",
"PRELIMINARY CLINICAL EVIDENCE indicates the drug has potential to address UNMET MEDICAL NEEDS for that condition."
],
"benefit": "All Breakthrough features (early intensive guidance) PLUS explicit eligibility for Accelerated Approval on surrogate/intermediate endpoints and flexible confirmatory-evidence options (e.g. real-world data, expanded registries).",
"timing": "With the IND or after; FDA responds within 60 days.",
"gotcha": "It is the regenerative-medicine analogue of Breakthrough \u2014 ONLY for cell/gene/tissue products. A small molecule or naked mAb cannot get RMAT, even with great data."
}{
"id": "accelerated_approval",
"name": "Accelerated Approval (AA)",
"type": "Approval pathway",
"criteria": [
"Drug treats a SERIOUS or life-threatening condition.",
"Provides a MEANINGFUL ADVANTAGE over AVAILABLE THERAPY.",
"Shows an effect on a SURROGATE ENDPOINT, or an INTERMEDIATE CLINICAL endpoint, that is REASONABLY LIKELY TO PREDICT clinical benefit (e.g. ORR/tumor shrinkage as a stand-in for survival)."
],
"benefit": "Approval can occur YEARS earlier, on the surrogate/intermediate endpoint, before overall-survival-type outcomes mature.",
"timing": "An approval pathway, discussed pre-NDA/BLA; not a 60-day designation.",
"gotcha": "REQUIRES a confirmatory (Phase 4) trial to verify clinical benefit; the trial should generally be UNDERWAY at approval. If it fails, the drug can be withdrawn. Needs a SURROGATE/INTERMEDIATE endpoint \u2014 a fully mature OS readout is regular approval, not AA."
}{
"id": "breakthrough",
"name": "Breakthrough Therapy (BTD)",
"type": "Development designation",
"criteria": [
"Drug treats a SERIOUS or life-threatening condition.",
"PRELIMINARY CLINICAL EVIDENCE (i.e. human data, not just nonclinical) indicates the drug may demonstrate SUBSTANTIAL IMPROVEMENT over AVAILABLE THERAPY ...",
"... on one or more CLINICALLY SIGNIFICANT ENDPOINT(s) (a durable, large effect \u2014 e.g. dramatic ORR/response vs a weak standard of care, or effect on a strong surrogate that represents a clear advance)."
],
"benefit": "All Fast Track features PLUS intensive FDA guidance on efficient drug development starting as early as Phase 1, and organizational commitment (senior managers / cross-disciplinary review).",
"timing": "Ideally by the end-of-Phase-2 meeting; FDA responds within 60 days.",
"gotcha": "The differentiator from Fast Track is the EVIDENCE TYPE and SIZE: BTD needs PRELIMINARY CLINICAL evidence of SUBSTANTIAL (not just any) improvement over AVAILABLE therapy. Nonclinical-only assets do not qualify."
}{
"id": "fast_track",
"name": "Fast Track",
"type": "Development designation",
"criteria": [
"Drug treats a SERIOUS or life-threatening condition.",
"Demonstrates potential to address an UNMET MEDICAL NEED, OR is a qualified infectious disease product.",
"Evidence bar is LOW: nonclinical data, or a plausible mechanistic / early clinical rationale, is enough \u2014 no efficacy data required."
],
"benefit": "Rolling review, more frequent FDA meetings/written communication, and eligibility for Accelerated Approval and Priority Review if criteria later met.",
"timing": "Any time, with the IND or after; FDA responds within 60 days.",
"gotcha": "Fast Track is about UNMET NEED + seriousness; it does NOT by itself speed the review clock \u2014 that is Priority Review."
}{
"id": "orphan",
"name": "Orphan Drug Designation",
"type": "Incentive designation",
"criteria": [
"Targets a RARE DISEASE/CONDITION: US prevalence < 200,000 patients (or a disease where development costs are not expected to be recovered from US sales).",
"Plausible scientific rationale that the drug treats the rare condition."
],
"benefit": "7 years of orphan market exclusivity on approval, tax credits for clinical trials, and waiver of the (large) PDUFA application user fee.",
"timing": "Any time before the marketing application is submitted.",
"gotcha": "Orphan status is about PREVALENCE/economics, NOT about how good the data is and NOT a faster review. It is independent of Fast Track / BTD / AA / Priority Review and stacks with them."
}{
"id": "priority_review",
"name": "Priority Review",
"type": "Review designation",
"criteria": [
"Application is for a drug that, if approved, would be a SIGNIFICANT IMPROVEMENT in the safety or effectiveness of treatment, diagnosis, or prevention of a SERIOUS condition (or qualifies via a Priority Review Voucher)."
],
"benefit": "Shortens the FDA REVIEW CLOCK to ~6 months (vs ~10 months standard).",
"timing": "Decided at the time the marketing application (NDA/BLA) is filed.",
"gotcha": "Acts only at REVIEW time on the FILED application \u2014 it does not affect the development program. A Rare Pediatric Disease PRV can also CONFER Priority Review on an unrelated product."
}{
"id": "rare_pediatric",
"name": "Rare Pediatric Disease (RPD) Designation + Priority Review Voucher",
"type": "Incentive designation (pediatric)",
"criteria": [
"Disease is a SERIOUS or life-threatening RARE disease (US prevalence < 200,000) ...",
"... that PRIMARILY AFFECTS individuals under age 18 (a pediatric population)."
],
"benefit": "On approval of the RPD product, the sponsor receives a TRANSFERABLE Priority Review Voucher (PRV) \u2014 sellable for ~$100M+ \u2014 redeemable to get Priority Review on any future application.",
"timing": "Designation before the marketing application; voucher issued at approval.",
"gotcha": "Must be PEDIATRIC-predominant, not just rare. The PRV is the prize (it can be sold), separate from any expedited pathway the asset itself uses."
}| Program | Qualifies? | Why (mapping facts → criteria) |
|---|---|---|
| RMAT | ✅ Yes — anchor designation | (1) Regenerative medicine therapy → autologous CAR-T ✓; (2) serious/life-threatening → 3L+ ES-SCLC, median OS a few months ✓; (3) preliminary clinical evidence addressing unmet need → Phase 1/2 confirmed ORR 55% vs 15–20%, no approved targeted 3L+ option ✓. |
| Breakthrough (BTD) | ✅ Yes (but redundant) | Serious condition + preliminary clinical evidence of substantial improvement over available therapy (55% vs 15–20% is large) ✓. But RMAT already includes all BTD benefits and is the cell-therapy analogue — so you take RMAT, not BTD. |
| Fast Track | ✅ Yes (but subsumed) | Serious + unmet medical need ✓. Lowest bar; its benefits are wholly contained within RMAT/BTD. Don't bother applying separately if pursuing RMAT. |
| Accelerated Approval (AA) | ✅ Yes — target approval pathway | Serious condition ✓; meaningful advantage over available therapy ✓; effect on a surrogate (ORR) reasonably likely to predict benefit, with OS not yet mature ✓. RMAT explicitly confers AA eligibility + flexible confirmatory evidence. |
| Orphan Drug | ✅ Yes | US prevalence 35,000 < 200,000 ✓. Stacks independently — gives 7-yr exclusivity, PDUFA fee waiver, tax credits. Apply this regardless. |
| Priority Review | ✅ Likely at filing | Would be a significant improvement in treatment of a serious condition ✓. Decided at BLA filing, not now. |
| Rare Pediatric Disease (RPD/PRV) | ❌ No | Requires a disease that primarily affects under-18s. SCLC is an adult disease (pediatric: false). Disqualified — no PRV. |
Precedent grounding: This maps almost exactly to Tisagenlecleucel (Kymriah) in R/R follicular lymphoma — an autologous CAR-T that took RMAT → Accelerated Approval on response endpoints → Orphan, with a confirmatory obligation. Pembrolizumab's melanoma approval is the canonical "durable ORR surrogate → AA with confirmatory trial" oncology precedent. ASSET-01 is squarely in this lane.
1. Now (Phase 1/2, IND active) — file RMAT + Orphan in parallel
- RMAT is your anchor: it gives all Breakthrough benefits (early intensive, senior-level FDA engagement) plus explicit AA eligibility and flexible confirmatory-evidence options (registries/RWD) — uniquely valuable for a one-time CAR-T where a classic randomized confirmatory trial is hard. FDA responds in 60 days.
- Orphan Drug in parallel — independent track (prevalence-based), zero downside, secures 7-yr exclusivity + fee waiver. File any time before BLA.
- Skip standalone Fast Track and BTD — both are fully subsumed by RMAT for a cell therapy. Filing them adds work without benefit. (Fast Track is your fallback only if RMAT were somehow denied.)
2. Leverage RMAT's early FDA access — design the AA package
- Use RMAT meetings to lock in ORR (+ duration of response) as the surrogate for AA and to pre-agree the confirmatory plan (ideally a confirmatory trial underway at the time of approval — the key AA gotcha). Negotiate flexible confirmatory evidence (expanded registry/RWD) given the regenerative-medicine context.
3. At BLA submission — Accelerated Approval + request Priority Review
- File the BLA seeking AA on the ORR/DoR surrogate before OS matures. Request rolling review (an RMAT/Fast Track feature) to submit modules as ready.
- Priority Review is determined at filing and is very likely to be granted (significant improvement in a serious condition) → ~6-month clock.
4. Post-approval — complete the confirmatory trial
- Verify clinical benefit (ideally OS/PFS). AA converts to full approval on success; failure risks withdrawal. Keep this trial enrolling before approval.
Stack RMAT (anchor) + Orphan now → develop with FDA → file for Accelerated Approval on the ORR surrogate with Priority Review and a confirmatory trial running. Do not pursue separate Fast Track/BTD (subsumed by RMAT) and you are not eligible for the Rare Pediatric PRV (adult disease).
⚠️ Two caveats to watch: (1) AA is conditional — have the confirmatory trial underway at approval or risk withdrawal; (2) durability matters — the "several responders >6 months" signal must hold up, as BTD/AA both hinge on a durable response, not just a high initial ORR.
Would you like me to sketch the parallel EMA strategy (PRIME + Conditional MA + EU Orphan), which mirrors this stack?
| Program | Qualifies? | Why (mapping facts → criteria) |
|---|---|---|
| RMAT | ✅ Yes — anchor designation | (1) Regenerative medicine therapy → autologous CAR-T ✓; (2) serious/life-threatening → 3L+ ES-SCLC, median OS a few months ✓; (3) preliminary clinical evidence addressing unmet need → Phase 1/2 confirmed ORR 55% vs 15–20%, no approved targeted 3L+ option ✓. |
| Breakthrough (BTD) | ✅ Yes (but redundant) | Serious condition + preliminary clinical evidence of substantial improvement over available therapy (55% vs 15–20% is large) ✓. But RMAT already includes all BTD benefits and is the cell-therapy analogue — so you take RMAT, not BTD. |
| Fast Track | ✅ Yes (but subsumed) | Serious + unmet medical need ✓. Lowest bar; its benefits are wholly contained within RMAT/BTD. Don't bother applying separately if pursuing RMAT. |
| Accelerated Approval (AA) | ✅ Yes — target approval pathway | Serious condition ✓; meaningful advantage over available therapy ✓; effect on a surrogate (ORR) reasonably likely to predict benefit, with OS not yet mature ✓. RMAT explicitly confers AA eligibility + flexible confirmatory evidence. |
| Orphan Drug | ✅ Yes | US prevalence 35,000 < 200,000 ✓. Stacks independently — gives 7-yr exclusivity, PDUFA fee waiver, tax credits. Apply this regardless. |
| Priority Review | ✅ Likely at filing | Would be a significant improvement in treatment of a serious condition ✓. Decided at BLA filing, not now. |
| Rare Pediatric Disease (RPD/PRV) | ❌ No | Requires a disease that primarily affects under-18s. SCLC is an adult disease (pediatric: false). Disqualified — no PRV. |
Precedent grounding: This maps almost exactly to Tisagenlecleucel (Kymriah) in R/R follicular lymphoma — an autologous CAR-T that took RMAT → Accelerated Approval on response endpoints → Orphan, with a confirmatory obligation. Pembrolizumab's melanoma approval is the canonical "durable ORR surrogate → AA with confirmatory trial" oncology precedent. ASSET-01 is squarely in this lane.
1. Now (Phase 1/2, IND active) — file RMAT + Orphan in parallel
- RMAT is your anchor: it gives all Breakthrough benefits (early intensive, senior-level FDA engagement) plus explicit AA eligibility and flexible confirmatory-evidence options (registries/RWD) — uniquely valuable for a one-time CAR-T where a classic randomized confirmatory trial is hard. FDA responds in 60 days.
- Orphan Drug in parallel — independent track (prevalence-based), zero downside, secures 7-yr exclusivity + fee waiver. File any time before BLA.
- Skip standalone Fast Track and BTD — both are fully subsumed by RMAT for a cell therapy. Filing them adds work without benefit. (Fast Track is your fallback only if RMAT were somehow denied.)
2. Leverage RMAT's early FDA access — design the AA package
- Use RMAT meetings to lock in ORR (+ duration of response) as the surrogate for AA and to pre-agree the confirmatory plan (ideally a confirmatory trial underway at the time of approval — the key AA gotcha). Negotiate flexible confirmatory evidence (expanded registry/RWD) given the regenerative-medicine context.
3. At BLA submission — Accelerated Approval + request Priority Review
- File the BLA seeking AA on the ORR/DoR surrogate before OS matures. Request rolling review (an RMAT/Fast Track feature) to submit modules as ready.
- Priority Review is determined at filing and is very likely to be granted (significant improvement in a serious condition) → ~6-month clock.
4. Post-approval — complete the confirmatory trial
- Verify clinical benefit (ideally OS/PFS). AA converts to full approval on success; failure risks withdrawal. Keep this trial enrolling before approval.
Stack RMAT (anchor) + Orphan now → develop with FDA → file for Accelerated Approval on the ORR surrogate with Priority Review and a confirmatory trial running. Do not pursue separate Fast Track/BTD (subsumed by RMAT) and you are not eligible for the Rare Pediatric PRV (adult disease).
⚠️ Two caveats to watch: (1) AA is conditional — have the confirmatory trial underway at approval or risk withdrawal; (2) durability matters — the "several responders >6 months" signal must hold up, as BTD/AA both hinge on a durable response, not just a high initial ORR.
Would you like me to sketch the parallel EMA strategy (PRIME + Conditional MA + EU Orphan), which mirrors this stack?
Rule-based eligibility checklist for ASSET-01 (DLL3 CAR-T in relapsed/refractory ES-SCLC), applying each program's qualifying criteria to the scenario facts. A strong agent recovers the same QUALIFIES/DOESN'T calls with the right deciding criterion, handles the surrogate-vs-mature-endpoint and regenerative-vs-not distinctions, and notes the Accelerated-Approval confirmatory-trial obligation.
| FDA program | Eligibility | Deciding criterion |
|---|---|---|
| Fast Track | QUALIFIES | Serious condition addressing an unmet need; low evidence bar (nonclinical rationale suffices). |
| Breakthrough Therapy | QUALIFIES | Preliminary clinical evidence of substantial improvement over available therapy. |
| Accelerated Approval | QUALIFIES | Serious + meaningful advantage + effect on a surrogate/intermediate endpoint reasonably likely to predict benefit. REQUIRES a confirmatory trial. |
| Priority Review | QUALIFIES | Would be a significant improvement for a serious condition; request at NDA/BLA filing (also obtainable via a Rare-Pediatric PRV). |
| RMAT | QUALIFIES | Regenerative-medicine therapy for a serious condition with preliminary clinical evidence of potential to address unmet need. (Use INSTEAD of BTD for regen products; adds AA + flexible confirmatory evidence.) |
| Orphan Drug | QUALIFIES | US prevalence 35,000 < 200,000. |
| Rare Pediatric Disease PRV | DOESN'T | DOESN'T: not a primarily pediatric disease. |
| → Recommended pathway stack | RMAT; Accelerated Approval (with confirmatory trial underway); Orphan Drug; Priority Review (at filing) | Designations are not mutually exclusive; sequence them across development (designation → development support → approval pathway → review). |